jensen2Clinical Immunologist

Key facts: Studies, doctorate in medicine and specialist training in immunology at the University of Vienna were supplemented by several years abroad, at the University Hospital Inselspital in Bern, Switzerland, and the University Clinic Rigshospital in Copenhagen, Denmark.

Today Erika Jensen-Jarolim chairs the unit for Comparative Immunology and Oncology, at the Institute for Pathophysiology and Allergy Research, Medical University Vienna. Further, she chairs the interuniversity Messerli Research Institute in Vienna, supported by the Swiss Messerli Foundation.
Erika Jensen-Jarolim is vice president of the Austrian Society for Allergology and Immunology (ÖGAI), chief editor of the World Allergy Organization Journal, is involved in several working groups of the European Academy of Allergy and Clinical Immunology (EAACI), the American Academy of Allergy, Asthma and Immunology (AAAAI) ), and is a member of the Austrian microbiome initiative amici.

She not only applies molecular allergology to diagnose allergy patients in her private practice AllergyCare®, but also scientifically concentrates on molecular allergology. In her research she also reaches out to the interface to oncology and, consequently, initiated the "AllergoOncology" field in 2006, which since has gained international recognition.

Her academic oeuvre comprises over 250 publications in PubMed and she is since many years a dedicated teacher of PhD and Master students.

Quotation: "Allergy is a global clinical problem, but the answer to it lies in the allergen molecules. Only when understanding the mechanisms will we have a chance to prevent, diagnose and treat allergies in our patients in an optimal way."

Selected publications:

  1. Singer, J., Weichselbaumer, M., Stockner, T., Mechtcheriakova, D., Sobanov, Y., Bajna, E., Wrba, F., Horvat, R., Thalhammer, J.G., Willmann, M., and Jensen-Jarolim, E. (2012). Comparative oncology: ErbB-1 and ErbB-2 homologues in canine cancer are susceptible to cetuximab and trastuzumab targeting. Molecular immunology 50, 200-209. PMID: 22424313
  2. Riemer, A.B., Untersmayr, E., Knittelfelder, R., Duschl, A., Pehamberger, H., Zielinski, C.C., Scheiner, O., and Jensen-Jarolim, E. (2007). Active induction of tumor-specific IgE antibodies by oral mimotope vaccination. Cancer research 67, 3406-3411. PMID: 17409451
  3. Untersmayr, E., Bakos, N., Scholl, I., Kundi, M., Roth-Walter, F., Szalai, K., Riemer, A.B., Ankersmit, H.J., Scheiner, O., Boltz-Nitulescu, G., and Jensen-Jarolim, E. (2005a). Anti-ulcer drugs promote IgE formation toward dietary antigens in adult patients. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 19, 656-658. PMID: 17227952
  4. Roth-Walter, F., Scholl, I., Untersmayr, E., Fuchs, R., Boltz-Nitulescu, G., Weissenbock, A., Scheiner, O., Gabor, F., and Jensen-Jarolim, E. (2004). M cell targeting with Aleuria aurantia lectin as a novel approach for oral allergen immunotherapy. The Journal of allergy and clinical immunology 114, 1362-1368. PMID: 15577836
  5. Ganglberger, E., Grunberger, K., Sponer, B., Radauer, C., Breiteneder, H., Boltz-Nitulescu, G., Scheiner, O., and Jensen-Jarolim, E. (2000a). Allergen mimotopes for 3-dimensional epitope search and induction of antibodies inhibiting human IgE. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 14, 2177-2184. PMID: 11053238

Other Publications extlink